| ENLIVEX LTD. IS-,01 |
| Israel |
| Gesundheit |
| IL0011319527 / A119KH |
| 1BT (Frankfurt) / ENLV (NASDAQ) |
| FRA:1BT, ETR:1BT, 1BT:GR, NASDAQ:ENLV |
| - |
| https://www.enlivex.com/ |
|
Enlivex Ltd. is a clinical-stage macrophage reprogramming immunotherapy company headquartered in Ness Ziona, Israel. The company focuses on the late-stage clinical development of Allocetra, a universal, off-the-shelf cell therapy designed to reprogra..
>Volltext.. |
| 62.17 Mio. EUR |
| 57.72 Mio. EUR |
| - |
| -12.9 Mio. EUR |
| 1086.52 Mio. EUR |
| 356.65 EUR |
| 0.56 Mio. EUR |
| 1.76 Mio. EUR |
| -9.71 Mio. EUR |
| 0.65 |
| - |
| - |
| - |
| - |
| - |
| - |
| ENLIVEX |
| 28.07.26 |
|
||||
|
||||
|
||||
|